Cargando…
Appropriate endpoints for evaluation of new antibiotic therapies for severe infections: a perspective from COMBACTE’s STAT-Net
PURPOSE: In this era of rising antimicrobial resistance, slowly refilling antibiotic development pipelines, and an aging population, we need to ensure that randomized clinical trials (RCTs) determine the added benefit of new antibiotic agents effectively and in a valid way, especially for severely i...
Autores principales: | Timsit, Jean-François, de Kraker, Marlieke E. A., Sommer, Harriet, Weiss, Emmanuel, Bettiol, Esther, Wolkewitz, Martin, Nikolakopoulos, Stavros, Wilson, David, Harbarth, Stephan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5487537/ https://www.ncbi.nlm.nih.gov/pubmed/28466147 http://dx.doi.org/10.1007/s00134-017-4802-4 |
Ejemplares similares
-
Optimizing the Design and Analysis of Clinical Trials for Antibacterials Against Multidrug-resistant Organisms: A White Paper From COMBACTE’s STAT-Net
por: de Kraker, Marlieke E A, et al.
Publicado: (2018) -
Linking antimicrobial resistance surveillance to antibiotic policy in healthcare settings: the COMBACTE-Magnet EPI-Net COACH project
por: Pezzani, Maria Diletta, et al.
Publicado: (2020) -
Surveillance of Resistance to New Antibiotics in an Era of Limited Treatment Options
por: Morel, Chantal M., et al.
Publicado: (2021) -
Industry incentives and antibiotic resistance: an introduction to the antibiotic susceptibility bonus
por: Morel, Chantal M., et al.
Publicado: (2020) -
Will 10 Million People Die a Year due to Antimicrobial Resistance by 2050?
por: de Kraker, Marlieke E. A., et al.
Publicado: (2016)